- In this edition, Molefy Pharma competed against 7 other projects.
- Molefy Pharma is working on the search for a cure for amyotrophic lateral sclerosis (ALS).
Moley Pharma, a spin-off of the CSIC in collaboration with ARQUIMEA dedicated to finding a cure for amyotrophic lateral sclerosis (ALS) through the AP-2 molecule, has won first prize in the eighth edition of the Investment Forum of the Science and Technology Park of Tenerife. The event, held as part of the second edition of Hub Intech, took place on 22 and 23 November at the Iberostar Heritage Grand Mencey.
The company, presented to the jury and the general public by Tania Ortuño, co-founder of Molefy Pharma, competed on this occasion with 7 other companies: Artist Development, Effiwaste, Fitenium, Kanara Labs, SecurityInthenet, Wonde Experience Group SL and Zen Biometrics. Ortuño received the award from the Tenerife Island Councillor for Innovation, Research and Development, Juan José Martínez, who said that ‘with this forum we aim to fill one of the gaps in the business projects of entrepreneurs, and that gap is access to investment’.
For her part, Tania Ortuño indicated that ‘it is very important for us to participate in these initiatives, as it allows us to make ourselves known. In addition, all the help from networking or the experience of the mentors is of great value for us to continue advancing’.
‘Ana Martínez and Carmen Gil, CSIC researchers who initiated the project that has given rise to Molefy, have been dedicated to researching molecules for more than 30 years. In our case, we have several molecules aimed at different diseases, the main one being AP-2, which is presented as a potential treatment for ALS’.
It is expected that Molefy Pharma will be able to start Phase I clinical trials in 2025 after completing the pre-clinical phase of the trials.
